Myotonic Dystrophy - Pipeline Review, H2 2016

  • ID: 3821646
  • Report
  • 60 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AMO Pharma Limited
  • F. Hoffmann-La Roche Ltd.
  • Marina Biotech, Inc.
  • WAVE Life Sciences Ltd.
  • MORE
Myotonic Dystrophy - Pipeline Review, H2 2016

Summary

‘Myotonic Dystrophy - Pipeline Review, H2 2016’, provides an overview of the Myotonic Dystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myotonic Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myotonic Dystrophy and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myotonic Dystrophy
- The report reviews pipeline therapeutics for Myotonic Dystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Myotonic Dystrophy therapeutics and enlists all their major and minor projects
- The report assesses Myotonic Dystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myotonic Dystrophy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Myotonic Dystrophy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myotonic Dystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AMO Pharma Limited
  • F. Hoffmann-La Roche Ltd.
  • Marina Biotech, Inc.
  • WAVE Life Sciences Ltd.
  • MORE
List of Figures

Introduction

Report Coverage

Myotonic Dystrophy Overview

Therapeutics Development

Pipeline Products for Myotonic Dystrophy - Overview

Pipeline Products for Myotonic Dystrophy - Comparative Analysis

Myotonic Dystrophy - Therapeutics under Development by Companies

Myotonic Dystrophy - Therapeutics under Investigation by Universities/Institutes

Myotonic Dystrophy - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Myotonic Dystrophy - Products under Development by Companies

Myotonic Dystrophy - Products under Investigation by Universities/Institutes

Myotonic Dystrophy - Companies Involved in Therapeutics Development

AMO Pharma Limited

BioMarin Pharmaceutical Inc.

F. Hoffmann-La Roche Ltd.

Ionis Pharmaceuticals, Inc.

Marina Biotech, Inc.

Sarepta Therapeutics, Inc.

WAVE Life Sciences Ltd.

Myotonic Dystrophy - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotides for Myotonic Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONISDMPK-2.5Rx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IUCT-169 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IUCT-290 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IUCT-309 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LR-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mexiletine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide 1 to Target Dystrophia Myotonica Protein Kinase for Myotonic Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Inhibit DM1 Protein Kinase for Myotonic Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRO-135 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-33 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target CUG RNA for Myotonic Dystrophy 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target RNA for Myotonic Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Myotonic Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Myotonic Dystrophy Type 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MBNL1 for Myotonic Dystrophy Type I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target RNA for Myotonic Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-149 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-152 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tideglusib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-0411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myotonic Dystrophy - Dormant Projects

Myotonic Dystrophy - Discontinued Products

Myotonic Dystrophy - Product Development Milestones

Featured News & Press Releases

Sep 19, 2013: AmorChem invests in the development of a therapeutic to treat myotonic dystrophy

Dec 20, 2012: Scripps Florida Scientists Create New Approach to Destroy Disease-Associated RNAs in Cells

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Myotonic Dystrophy, H2 2016

Number of Products under Development for Myotonic Dystrophy - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Myotonic Dystrophy - Pipeline by AMO Pharma Limited, H2 2016

Myotonic Dystrophy - Pipeline by BioMarin Pharmaceutical Inc., H2 2016

Myotonic Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Myotonic Dystrophy - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016

Myotonic Dystrophy - Pipeline by Marina Biotech, Inc., H2 2016

Myotonic Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2016

Myotonic Dystrophy - Pipeline by WAVE Life Sciences Ltd., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Myotonic Dystrophy - Dormant Projects, H2 2016

Myotonic Dystrophy - Discontinued Products, H2 2016 56List of Figures

Number of Products under Development for Myotonic Dystrophy, H2 2016

Number of Products under Development for Myotonic Dystrophy - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AMO Pharma Limited
BioMarin Pharmaceutical Inc.
F. Hoffmann-La Roche Ltd.
Ionis Pharmaceuticals, Inc.
Marina Biotech, Inc.
Sarepta Therapeutics, Inc.
WAVE Life Sciences Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll